The authors point out that data collected through a questionnaire filled out by study participants does not necessarily coincide with the truth, as they tend to describe their unhealthy addiction on a smaller scale than it is (77)
Due to this operational issue, CMS proposes in 428.201(b) to codify the policy established in section 30.1 of the revised Medicare Part D Drug Inflation Rebate Guidance whereby CMS would exclude from Part D drug inflation rebate calculations drugs and biologicals that meet the definition of a Part D rebatable drug but for which the manufacturer does not have an MDRP agreement in effect with the HHS Secretary under section 1927 of the Act at any point during the applicable period, or the Part D rebatable drug is one that does not meet the definition of a COD
FDA plays a central role in expediting the availability of safe and effective cancer therapies, including through the expansion and diversification of clinical trials
For example, lessons learned from the CMS Innovation Center's ACO models may be incorporated into the Shared Savings Program
Since we believe that this will result in expanded use of the transfer of care modifiers, which will have a corresponding effect on the payment for the affected services, we have reflected this in our utilization estimates accordingly (see download file for this proposed rule titled CY 2025 PFS final rule 2023 Utilization Data Crosswalked to 2025 at ) and anticipate more global surgical packages and post-op care to be billed separately using the modifiers, which could have payment consequences for a selection of high-volume global surgery codes
